A New Era of Diabetes Management

GLP-1 Medication Weight Loss Side Effect Sparks Change

Authored by:

Jeff Auten, PharmD
Director of Clinical Consulting

Hugh Gallagher
Sr. Vice President of Growth and Business Development

Leaf Health

Table of Contents

Introduction

Glucagon-like peptide (GLP-1) medications have sparked a new era in diabetes management, offering an exciting breakthrough that promises to change the lives of millions. Originally developed to regulate the blood sugar levels of those living with diabetes, GLP-1 drugs have recently seen a surge in consumer attention due to a specific side effect—weight loss.[1]

Now, GLP-1 medications are reshaping the landscape of diabetes treatment strategies. As individuals with diabetes grapple with the challenges of managing their condition, GLP-1 medications have become an alluring solution. These newest discoveries have consequently encouraged researchers, healthcare professionals, and patients to reevaluate traditional approaches to care.

In this whitepaper, we explore the multifaceted benefits of GLP-1 treatments, as well as the efficacy and side effects associated with them.

An Overview of GLP-1 Medications & Uses

GLP-1 agonists are a subclass of medications used to treat both type 2 diabetes and obesity. They work by mimicking the effects of a natural hormone called GLP-1, which helps to regulate blood sugar levels by stimulating the release of insulin.[2] By activating GLP-1 receptors in the body, these drugs can lower blood glucose levels, reduce appetite, and lead to weight loss.

Common Types of GLP-1 Medications:

- Ozempic (Semaglutide)
- Trulicity (Dulaglutide)
- Bydureon Bcise (Exenatide)
- Byetta (Exenatide)
- Saxenda (Liraglutide)
- Adlyxin (Lixisenatide)
- Wegovy (Semaglutide)
- Rybelsus (Semaglutide)
- Mounjaro (Tirzepatide)
- Zepbound (Tirzepatide)

Within this subclass, certain drugs are indicated for both diabetes and obesity treatments but are marketed under different brand names. For instance, Ozempic (for diabetes) and Wegovy (for obesity) both contain semaglutide, while Victoza (for diabetes) and Saxenda (for obesity) contain liraglutide.[3] Mounjaro (tirzepatide) exhibits a dual mechanism as GLP-1 and gastric inhibitory polypeptide (GIP) agonists. Its obesity treatment parallel is Zepbound.

Here is a quick-view chart to help clarify the above:

Peptide:	For Diabetes Treatment:	For Obesity Treatment:
Semaglutide	Ozempic	Wegovy
Liraglutide	Victoza	Saxenda
Tirzepatide	Mounjaro	Zepbound

Given the overlap between diabetes and obesity, many patients benefit from these medications to manage these conditions concurrently. While most insurance plans cover diabetes medications, there are exclusions for obesity treatments. Prior authorizations may be required. Consequently, due to the broader accessibility of diabetes medications compared to those for obesity, there's potential for off-label use of the former in patients without diabetes but with obesity.

Supply Chain Issues

Supply chain issues have become a significant concern across the pharmaceutical industry, and this applies to GLP-1 agonists as well.

The process of producing and distributing medications is often a complex and multi-faceted operation. It requires the involvement of various suppliers and manufacturers, each specializing in different aspects of the process, such as raw material procurement, formulation, testing, and packaging. Furthermore, the production process itself can be highly regulated and subject to various quality and safety standards that must be strictly adhered to. Additionally, the distribution of medications involves intricate logistics planning, as they need to be transported under controlled conditions to ensure their efficacy and safety. All these factors combined make the production and distribution of medications a challenging and intricate process.

These disruptions impact patients reliant on GLP-1 agonists for managing their diabetes or obesity and pose challenges for healthcare providers and insurers in ensuring continuous access to essential medications. Collaborative efforts among pharmaceutical companies, regulatory bodies, and other supply chain stakeholders are crucial to providing a stable and resilient supply of GLP-1 agonists for patients nationwide.

Challenges Faced Overview:

- Raw material shortages
- Manufacturing disruptions
- Transportation delays
- Fluctuations in demand
- Regulatory hurdles
- Public health events (like COVID-19)

Off-Label Use: A Cause for Concern

Off-label use of GLP-1 agonists, while not officially approved for certain conditions, has garnered attention for its potential therapeutic benefits beyond indicated uses. Despite being primarily indicated for type 2 diabetes, GLP-1 agonists have shown promise in other areas, such as combatting obesity and even cardiovascular disease.

Research suggests that GLP-1 agonists may exert favorable effects on glucose metabolism, weight loss, and cardiovascular health, making them attractive candidates for off-label use in conditions where these benefits are desired. However, off-label use entails inherent risks, including the following:

- ✖ Limited evidence of efficacy
- ✖ Safety concerns in non-approved indications
- ✖ Potential adverse effects
- ✖ Reimbursement challenges

The off-label use is exacerbating existing supply chain issues, too, by placing additional strain on the production and distribution of these medications. When medications are prescribed for conditions beyond approved uses, it can lead to increased demand without corresponding increases in production capacity. This heightened demand can strain the already delicate balance of the supply chain, potentially resulting in more shortages or delays in accessing drugs for those who rely on them. Off-label use creates challenges for pharmaceutical companies in managing inventory levels effectively due to uncertainties in demand forecasting and resource allocation.



Influencers & Celebrities Fuel the Hype[3]



GLP-1 medications have recently found themselves in the spotlight on social media platforms like Instagram, TikTok, and YouTube. Ozempic and Wegovy are being highlighted in particular. Video content covering information on these drugs and, oftentimes, weight loss success stories centered around the intake of the medications finds its way to phone and computer screens worldwide, including in the US.

GLP-1 Drugs Have Branched Out Across Social Media Platforms:

- #Ozempic has been viewed over 274 million times.
- Celebrities and influencers are sharing their experiences with GLP-1 drugs.
- The term “Post-Ozempic body” is trending.
- Businesses are using it to promote other procedures.

It’s not just a swarm of social media influencers—celebrities and even tech moguls have shared their positive experiences, specifically with Ozempic and Wegovy, which has helped spread awareness about their benefits.

Celebrities Have Spoken About Taking GLP-1 Drugs for Weight Loss[4]

Mounjaro:	**Ozempic:**	**Wegovy:**
Whoopi Goldberg	Stassi Schroeder	Elon Musk
Sunny Hostin	Tracy Morgan	Oprah Winfrey*

Although there are those in Hollywood against the medications’ usage for weight loss, the popularity of GLP-1 drugs continues to trend upward due in part to influencers and celebrities sharing their stories.

The Benefits and Efficacy

GLP-1 medications provide a holistic approach to diabetes care, addressing multiple facets of the condition while reducing the risk of future complications. They present a versatile solution for diabetes management, offering a host of advantages:

- Enhanced insulin secretion in response to glucose levels, improving blood sugar control without inducing hypoglycemia.
- Slowed gastric emptying, reducing postprandial glucose spikes, aiding in weight management efforts.
- Cardiovascular benefits, including a decreased risk of major adverse cardiovascular events.[5]

Wegovy Trial Overview[5]

Wegovy injections have recently been approved to help prevent life-threatening cardiovascular events in adults who are obese or overweight. It's the first weight loss medication proven to lower cardiovascular risk, making it a major advance for public health.

A double-blind, multi-national, multi-center, placebo-controlled trial randomly assigned over 17,600 participants to receive Wegovy or a placebo, studying its efficacy and safety. Both groups received standard medical treatment for the management of blood pressure and cholesterol. Additionally, healthy lifestyle counseling, including diet and physical activity advice, was also given.

Wegovy was found to reduce the risk of major adverse cardiovascular events like death, heart attacks, and strokes. The trial showed that for people who are overweight or obese and have heart disease but not diabetes, using a once-a-week injection of semaglutide under the skin led to a 20% decrease in serious heart problems over an average treatment period of 33 months.

The Side Effects[6]



Research on GLP-1 implications is still underway but reported side effects include the following:

- Nausea
- Vomiting
- Diarrhea
- Excessive belching
- Abdominal pain
- Pancreatitis

Notably, GLP-1 treatments have a lower risk of hypoglycemia compared to other diabetic medications. Treatment primarily involves supportive care measures such as prescribing antiemetics to manage excessive nausea and vomiting.

Conclusion

GLP-1 medications offer promising avenues for both diabetes treatment and weight management. These medications not only improve blood sugar control but also aid in weight loss efforts, with potential reductions of up to 15-20%. As research continues to uncover the multifaceted benefits of GLP-1 medications, their applications in managing diabetes and promoting weight loss hold considerable significance in the ongoing fight against obesity and obesity-related diseases.

Sources:

1. https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/expert-answers/byetta/faq-20057955
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5556578/#:~:text=GLP%2D1%20receptor%20agonists%20are%20well%20suited%20for%20early%20use,hypoglycemia%20is%20low%20(38)
3. https://www.goodrx.com/classes/glp-1-agonists
4. https://people.com/celebrities-ozempic-wegovy-what-theyve-said-7104926
5. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
6. https://www.ncbi.nlm.nih.gov/books/NBK551568/

*Oprah has spoken out about using GLP-1 medications like Ozempic and Wegovy but keeps her specific choice to herself, though many think it is Wegovy.

About Leaf Health

At Leaf Health, our aim is to help our clients tackle the increasing costs of prescription drugs. We do this by coming up with innovative strategies that work, all while keeping patient care front and center. With over three decades of experience in the industry, our team takes a hands-on, customer-first approach to crafting and executing personalized plans that fit each client like a glove. Want to know more? **Visit leafhealth.net to learn more.**